Retatrutide is an advanced triple hormone receptor agonist that simultaneously stimulates GLP-1, GIP, and glucagon receptors. In cutting-edge metabolic research, this peptide has demonstrated significant reductions in body weight and improvements in glycemic control.
Research focuses include:
-
Triple hormone pathway modulation for enhanced energy expenditure and reduced appetite.
-
Advanced obesity research, showing greater efficacy than dual-agonist treatments like Tirzepatide.
-
Improvements in insulin action, lipid profile, and fatty liver models.
-
Increased thermogenesis and metabolic rate, driven by glucagon receptor activity.
Retatrutide represents the next evolution in incretin-based research for weight loss and metabolic disease management.
Reconstitution Instructions:
Reconstitute with BAC water. Refrigerate after reconstitution and use under sterile research conditions.
For research purposes only. Not for human consumption.
Reviews
There are no reviews yet.